Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

References

• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS InvestigatorsAm J Ophthalmol200013042944011024415
   PubMed Web of Science ®Google Scholar
• KastelanSTomicMMetezSKSalopek-RabaticJHow ocular surface disease impacts the glaucoma treatment outcomeBiomed Res Int2013201369632824224176
   PubMed Web of Science ®Google Scholar
• SambharaDArefAAGlaucoma management: relative value and place in therapy of available drug treatmentsTher Adv Chronic Dis20145304324381726
   PubMedGoogle Scholar
• DietleinTSHermannMMJordanJFThe medical and surgical treatment of glaucomaDtsch Arztebl Int200910659760519890428
   PubMed Web of Science ®Google Scholar
• StewartRHKimbroughRLWardRLBetaxolol vs timolol. A six-month double-blind comparisonArch Ophthalmol198610446483510612
   PubMed Web of Science ®Google Scholar
• ZimmermanTJKaufmanHETimolol. A beta-adrenergic blocking agent for the treatment of glaucomaArch Ophthalmol197795601604322648
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• UusitaloHPillunatLERopoAEfficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III studyActa Ophthalmol201088121920420586
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol200212070171312049574
   PubMed Web of Science ®Google Scholar
• AptelFCucheratMDenisPEfficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trialsEur J Ophthalmol20122251822167538
   PubMed Web of Science ®Google Scholar
• Xalatan^®. Package insertNew York, NY, USAPfizer Inc2011
   Google Scholar
• Timoptic^®. Package insertWhitehouse Station, NJ, USAMerck & Co2005
   Google Scholar
• CostaVPMoreiraHPaoleraMDde Moraes SilvaMREfficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapyClin Ophthalmol2012669970622654495
   PubMedGoogle Scholar
• HigginbothamEJFeldmanRStilesMDubinerHLatanoprost and timolol combination therapy versus monotherapy: one-year randomized trialArch Ophthalmol200212091592212096962
   PubMed Web of Science ®Google Scholar
• InoueKFujimotoTHigaREfficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapyClin Ophthalmol2012677177522693419
   PubMedGoogle Scholar
• InoueKOkayamaRHigaRWakakuraMTomitaGAssessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combinationClin Ophthalmol2012660761222553420
   PubMedGoogle Scholar
• PalmbergPKimEEKwokKKTresslerCSA 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapyEur J Ophthalmol20102070871820099236
   PubMed Web of Science ®Google Scholar
• PfeifferNA comparison of the fixed combination of latanoprost and timolol with its individual componentsGraefes Arch Clin Exp Ophthalmol200224089389912486510
   PubMed Web of Science ®Google Scholar
• ChengJWChengSWGaoLDLuGCWeiRLIntraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysisPLoS One20127e4507923028770
   PubMed Web of Science ®Google Scholar
• HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
   PubMedGoogle Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med200712071371917679131
   PubMed Web of Science ®Google Scholar
• InoueKOkayamaRHigaRSawadaHWakakuraMTomitaGOcular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combinationJ Ocul Pharmacol Ther20112758158722011049
   PubMed Web of Science ®Google Scholar
• KwonYHFingertJHKuehnMHAlwardWLPrimary open-angle glaucomaN Engl J Med20093601113112419279343
   PubMed Web of Science ®Google Scholar
• ADIS R&D Insight Available from: http://bi.adisinsight.comAccessed January 20, 2014
   Google Scholar
• HorsleyMBKahookMYEffects of prostaglandin analog therapy on the ocular surface of glaucoma patientsClin Ophthalmol2009329129519668581
   PubMedGoogle Scholar
• BaudouinCde LunardoCShort-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteersBr J Ophthalmol19988239429536878
   PubMed Web of Science ®Google Scholar
• BursteinNLPreservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneasInvest Ophthalmol Vis Sci1980193083137358482
   PubMed Web of Science ®Google Scholar
• HerrerasJMPastorJCCalongeMAsensioVMOcular surface alteration after long-term treatment with an antiglaucomatous drugOphthalmology199299108210881495787
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea20082733934318362664
   PubMed Web of Science ®Google Scholar
• KuppensEVde JongCAStolwijkTRde KeizerRJVan BestJAEffect of timolol with and without preservative on the basal tear turnover in glaucomaBr J Ophthalmol1995793393427742279
   PubMed Web of Science ®Google Scholar
• NakagawaSUsuiTYokooSToxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheetsInvest Ophthalmol Vis Sci2012535154516022695966
   PubMed Web of Science ®Google Scholar
• NoeckerRJHerrygersLAAnwaruddinRCorneal and conjunctival changes caused by commonly used glaucoma medicationsCornea20042349049615220734
   PubMed Web of Science ®Google Scholar
• NornMSOpauszkiAEffects of ophthalmic vehicles on the stability of the precorneal filmActa Ophthalmol (Copenh)197755233465897
   PubMed Web of Science ®Google Scholar
• OkaharaAKawazuKLocal toxicity of benzalkonium chloride in ophthalmic solutions following repeated applicationsJ Toxicol Sci20133853153723824009
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
   PubMed Web of Science ®Google Scholar
• WilsonLATo preserve or not to preserve, is that the question?Br J Ophthalmol1996805835848795365
   PubMed Web of Science ®Google Scholar
• WilsonWSDuncanAJJayJLEffect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and manBr J Ophthalmol1975596676691203224
   PubMed Web of Science ®Google Scholar
• YalvacISGedikogluGKaragozYEffects of antiglaucoma drugs on ocular surfaceActa Ophthalmol Scand1995732462487493237
   PubMedGoogle Scholar
• BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol20088671672618537937
   PubMed Web of Science ®Google Scholar
• GeorgievGAYokoiNKoevKSurface chemistry study of the interactions of benzalkonium chloride with films of meibum, corneal cells lipids, and whole tearsInvest Ophthalmol Vis Sci2011524645465421474774
   PubMed Web of Science ®Google Scholar
• GeorgievGAYokoiNIvanovaSKrastevRLalchevZSurface chemistry study of the interactions of pharmaceutical ingredients with human meibum filmsInvest Ophthalmol Vis Sci2012534605461522695955
   PubMed Web of Science ®Google Scholar
• KahookMYTravoprost Z opthalmic solution with sofZia: clinical safety and efficacyExp Rev Ophthal20072363368
   Google Scholar
• YeeRWNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther20062351151917050493
   PubMed Web of Science ®Google Scholar
• Good Clinical Practice: E6 Guidelines of the International Conference of HarmonisationClinical Trials RegistryIndia Available from: www.ctri.nic.in. CTRI identifier: CTRI/2011/091/000077Accessed May 19, 2014
   Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther20132938238923231442
   PubMed Web of Science ®Google Scholar
• SchwennOHeckmannBGuzyCMillerPJLong-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional studyBMC Ophthalmol2010102120825668
   PubMed Web of Science ®Google Scholar
• GurwitzJHGlynnRJMonaneMTreatment for glaucoma: adherence by the elderlyAm J Public Health1993837117168484454
   PubMed Web of Science ®Google Scholar
• KassMAGordonMMorleyREJrMeltzerDWGoldbergJJCompliance with topical timolol treatmentAm J Ophthalmol19871031881933812621
   PubMed Web of Science ®Google Scholar
• PatelSCSpaethGLCompliance in patients prescribed eyedrops for glaucomaOphthalmic Surg1995262332367651690
   PubMedGoogle Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol200714453354017686450
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma20031239339814520147
   PubMed Web of Science ®Google Scholar
• KonstasAGHaidichABRossettiLWebersCProstaglandin-timolol fixed combinations efficacy: myth or reality?Eur J Ophthalmol2012221422167537
   PubMed Web of Science ®Google Scholar
• DuoTrav. Summary of Product CharacteristicsSurrey, UKAlcon Laboratories (UK) Ltd2013
   Google Scholar
• AiharaMOtaniSKozakiJLong-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprostJ Glaucoma201221606421278589
   PubMed Web of Science ®Google Scholar